AstraZeneca

(PRESS RELEASE) CAMBRIDGE, 20-Nov-2020 — /EuropaWire/ — AstraZeneca (LON: AZN), a global, science-led biopharmaceutical company, has announced the US Food and Drug Administration (FDA) approval of its Imfinzi (durvalumab) for an additional dosing option, a 1,500mg fixed dose every four … Read the full press release →

(PRESS RELEASE) CAMBRIDGE, 14-Aug-2020 — /EuropaWire/ — Global science-led biopharmaceutical company AstraZeneca (LSE/STO/NYSE: AZN) has announced it signed an agreement with the European Commission (EC) for the supply of up to 400 million doses of the AZD1222 COVID-19 vaccine. Building … Read the full press release →

ACE-CL-001 trial showed an overall response rate of 97% with a sustained safety profile for previously untreated patients after more than four years In pivotal ASCEND trial, 82% of patients with relapsed or refractory disease treated with Calquence remained progression … Read the full press release →

(PRESS RELEASE) CAMBRIDGE, 5-Jun-2020 — /EuropaWire/ — British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca announced it will present new data across continuum of care from its broad renal portfolio during the 57th virtual congress of the European Renal Association – … Read the full press release →

(PRESS RELEASE) CAMBRIDGE, 22-May-2020 — /EuropaWire/ — Enhertu, jointly developed by British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca and the second-largest pharmaceutical company in Japan Daiichi Sankyo (Daiichi Sankyo Company, Limited), has just been granted Orphan Drug Designation (ODD) in … Read the full press release →

The company received support of more than $1bn from the US Biomedical Advanced Research and Development Authority (BARDA) Broad and equitable supply of the vaccine throughout the world at no profit during the pandemic First agreements for at least 400 … Read the full press release →

The trial, called CALAVI, will assess the effect of Calquence on the exaggerated immune response of patients hospitalised with COVID-19 infection (PRESS RELEASE) CAMBRIDGE, 14-Apr-2020 — /EuropaWire/ — Pharmaceutical giant AstraZeneca to begin a randomised, global clinical trial to assess … Read the full press release →

(PRESS RELEASE) CAMBRIDGE, 26-Mar-2020 — /EuropaWire/ — Science-led biopharmaceutical group AstraZeneca (LSE/STO/NYSE: AZN) has announced that its Lokelma (sodium zirconium cyclosilicate) is now approved in Japan. It is used for the treatment of patients with hyperkalaemia (elevated levels of potassium … Read the full press release →

(PRESS RELEASE) BASEL, 6-Jan-2020 — /EuropaWire/ — ChemChina and Sinochem announce the creation of Syngenta Group. The new holding company is the consolidation of both companies’ agricultural assets. Mark Patrick, Chief Financial Officer (CFO) and member of the Syngenta Executive … Read the full press release →

AstraZeneca / BenevolentAI artificial intelligence collaboration will accelerate drug discovery Potential new drugs discovery in the area of chronic kidney disease and idiopathic pulmonary fibrosis (PRESS RELEASE) CAMBRIDGE / LONDON, 30-Apr-2019 — /EuropaWire/ — New partnership, announced today, by AstraZeneca … Read the full press release →

27 scientific presentations, including long-term data from Calquence in mantle cell lymphoma and updated early-phase trial results in chronic lymphocytic leukaemia New data on six medicines and potential new medicines across a variety of blood cancers demonstrate breadth of haematology portfolio … Read the full press release →

CAMBRIDGE, 07-Nov-2018 — /EuropaWire/ — AstraZeneca has entered into an agreement with Covis Pharma B.V. (Covis Pharma) to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated with … Read the full press release →

AstraZeneca’s first Breakthrough Therapy Designation for a respiratory medicine Designation based on Phase IIb PATHWAY data that demonstrated tezepelumab significantly reduced asthma exacerbations compared to placebo in severe asthma CAMBRIDGE, 12-Sep-2018 — /EuropaWire/ — AstraZeneca and its partner Amgen Inc. (Amgen) … Read the full press release →

Lynparza met primary endpoint of progression-free survival in women with BRCA-mutated advanced ovarian cancer and showed a safety profile consistent with previous trials AstraZeneca and MSD’s Lynparza is the only PARP inhibitor to demonstrate significant activity in the 1st-line maintenance … Read the full press release →

Trial meets the primary endpoint of durable complete response Majority of patients who had a complete response had no evidence of any remaining detectable cancer cells Phase III clinical trial results served as basis for recent US FDA regulatory submission … Read the full press release →

Imfinzi is the only immunotherapy approved for patients with unresectable Stage III non-small cell lung cancer Imfinzi showed an 11.2 month improvement in median progression-free survival (16.8 months compared to 5.6 months on placebo) CAMBRIDGE, 22-Feb-2018 — /EuropaWire/ — AstraZeneca and … Read the full press release →

Lynparza is the first PARP inhibitor approved in Japan Lynparza tablets approved as maintenance treatment for women with platinum-sensitive relapsed ovarian cancer regardless of BRCA mutation status CAMBRIDGE, 22-Jan-2018 — /EuropaWire/ — AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, … Read the full press release →

Imfinzi improves progression-free survival (PFS) by more than 11 months compared to standard of care and is the first medicine to show superior PFS in this setting Data presented at the ESMO 2017 Congress follows FDA’s recent Breakthrough Therapy Designation … Read the full press release →

Phase III FLAURA trial results show Tagrisso reduced the risk of progression or death by more than half, with consistent benefit across all subgroups, including patients with and without brain metastases Unprecedented median progression-free survival (PFS) of 18.9 months compared … Read the full press release →

Uncovering the molecular mechanism behind a rare genetic risk factor of Alzheimer’s disease points to a new therapeutic target HEIDELBERG, 04-Sep-2017 — /EuropaWire/ — A gene called triggering receptor expressed on myeloid cells 2, or TREM2, has been associated with numerous … Read the full press release →